Summary
Ketanserin is a serotonin antagonist with age-related antihypertensive efficacy. Its effects on left ventricular (LV) function and hypertrophy have not been adequately reported. We studied noninvasively 54 elderly hypertensives before and 6 months after ketanserin monotherapy. Mean blood pressure was controlled (174/101 to 145/86 mmHg, p<0.0001) with no heart rate changes. LV dimensions and volumes remained unchanged, as did all LV ejection indices, thus preserving LV output (p=ns). Total peripheral resistances fell (from means of 1986 to 1615 dynes, cm.s-5, p<0.0001), as did LV systolic wall stresses. Mean LV mass was reduced (248 to 237 g, p<0.0001), mainly due to interventricular septum thinning (11.8 to 11.1 mm, p<0.0001), resulting in a decrease in mean LV cross-sectional area (21.3 to 20.5 cm2, p<0.0001) and mass/volume ratio (2.14 to 2.01 p=0.0001). Thus, LV hypertrophy regression did not affect contractility (LV mass index relation to stress/end-systolic volume index, r=−0.558 before and r=−0.564 after ketanserin therapy). It is concluded that ketanserin is an effective antihypertensive agent in the elderly that reduces LV hypertrophy indices and maintains cardiac output, with no concomitant burdening on LV hemodynamics.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kannel WB, Abbott RD. A prognestic comparison of asymptomatic left ventricular hypertrophy and unrecognized myocardial infarction. The Framingham study. Am Heart J 1986;111:391–397.
Vanhoutte P, Amery A, Birkenhäger W, et al. Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin. Hypertension 1988;2:112–133.
Sahn DJ, DeMaria A, Kisslo J, Weyman A. The committee on M-mode standardization of the American Society of Echocardiography: Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978;58: 1072–1078.
Kronic G, Slany J, Mösslacher H. Comparative value of eight M-mode echocardiographic formulas for determining left ventricular strole volume. A correlative study with thermodilution and left ventricular single-plane cineangiography. Circulation 1979;60:1308–1316.
Devereaux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55:613–619.
Reichek N, Wilson J St John, Sutton M, Plappert TA, Goldberg S, Hirshfield JW. Noninvasive determination of left ventricular end-systolic stress: Validation of the method and initial application. Circulation 1982;65:99–108.
Vensel LA, Deveraux RB, Pickering TG, Herrold EM, Borer JS, Laragh JH. Cardiac structure and function in renovascular hypertension produced by unilateral and bilateral renal artery stenosis. Am J Cardiol 1986;58:575–582.
Fouad-Tarazi FM, Liebson P. Echocardiographic studies of regression of left ventricular hypertrophy in hypertension. Hypertension 1987;9(Suppl 11):66–68.
Fagard R, Fiocchi R, Lijnen P, et al. Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension. Br Heart J 1984;51:149–156.
Symoens J, Janssens M. Ketanserin: A novel cardiovascular drug. Drug Dev Res 1986;8:159–172.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vyssoulis, G.P., Karpanou, E.A., Pitsavos, C.E. et al. Left ventricular hypertrophy regression and function changes with ketanserin in elderly hypertensives. Cardiovasc Drug Ther 4, 81–84 (1990). https://doi.org/10.1007/BF00053433
Issue Date:
DOI: https://doi.org/10.1007/BF00053433